, and the Univ. of Virginia, Charlottesville, VA. The role of Aeromonas (&) in the etiology of pediatric diarrhea is incompletely defined. It is unclear whether identification of isolates a t the species level or performance of toxigenicity studies help distinguish pathogenic from non-pathogenic strains. We isolated Aer from 33 of 704 children whose fecal specimens were submitted t o t h e Microbiology Laboratory of Children's Medical Center, Dallas, over a I-year period. Isolates were identified as & using the API 20E system. Additional tests performed on 29 strains included gas from glucose, salicin fermentation, growth in KCN, esculin hydrolysis, and elastase production. A. caviae was the predominant species (n = 19, 66%). A. sobria and A. hydrophila accounted for 3 each and 4 (14%) strains could not be speciated. Toxin production by Aer was studied using CHO cell, adrenal Y I cell, suckling mouse, and rabbit ileal loop assays. Twelve (39%) of 31 strains were positive in a t least one of these assays including 3 (17%) of 18 A. caviae and all 9 non-caviae strains tested. Two toxigenic strains were from asymptomatic older children. Toxigenic strains were significantly more likely to be positive for arginine dihydrolase (p <0.05), lysine decarboxylase (p <0.001), and Voges-Proskauer reaction (p <0.01), produce gas from glucose (p <0.001), and not ferment arabinose (p c0.005) compared with non-toxigenic strains. We conclude that & differentiation a t the species level is of limited clinical value and that several biochemical reactions can serve as markers for toxin production. In spite of a greater awareness and current obstetrical practices, the incidence of n e a~t a l I W is increasing. Medicine Wash U., St. Louis, MO. We administered live attenuated varicella vaccine to 187 healthy adults seronegative to varicella-zoster virus (VZV); 176 have been followed at least 2 mos. 1211176 (69%) received 2 doses about 3 months apart. Side effects after 1 dose were: local reactions in 18 (lo%), rash in 12 (7%), & fever in 4 (2%). Side effects were less freauent after the 2nd dose. Vaccine associated rash was mild (mean 14 lesions, ra'nge 1-100). Vaccine type virus was isolated from 1 adult with a total of 8 lesions, 1 mo. after vaccination; there was no spread of vaccine virus to others. Seroconversions to VZV, measured by fluorescent antibody to membrane antigen (FAMA) were: after 1 dose 1361169 (80%), & after 2 doses 1141121 (94%). 22 seroconverted only after the 2nd dose; 7 (6%) failed to seroconvert after 2 doses. Positive antibody responses have been detected after 1 yr in 44/67 (66%), after 2-3 yr.in 19/28 (68%), & after 4-6 yr in 10113 (77%). Ten have had a household exposure to varicella after as long as 7 years (mean 3 yrs); 6 (60%) developed at least some evidence of clinical varicella with 1-40 lesions (mean 16) but no toxicity. Seropositives (5110) rarely developed clinical symptoms; 1 had 1 vesicle. There were a total of 10 cases of mild varicella in adult vaccinees with 1-58 lesions, (mean lo), 4-72 months after immunization. Wild type virus was isolated from 2 MDs, but there was n o spread. Clinical infection was likely to occur in those seronegative at exposure (718, 88%) but the illness was still very mild. Varicella vaccine has the potential to control but not prevent nosocomial varicella. Varicella vaccine is less protective for healthy adults than for healthy children, but it modifies the illness even if VZV antibodies are no longer detectable. 
the species level is of limited clinical value and that several biochemical reactions can serve as markers for toxin production. In spite of a greater awareness and current obstetrical practices, the incidence of n e a~t a l I W is increasing. The mthers of 50-70% of these infants have no hx of genital HSV Medicine Wash U., St. Louis, MO. We administered live attenuated varicella vaccine to 187 healthy adults seronegative to varicella-zoster virus (VZV); 176 have been followed at least 2 mos. 1211176 (69%) received 2 doses about 3 months apart. Side effects after 1 dose were: local reactions in 18 (lo%), rash in 12 (7%), & fever in 4 (2%). Side effects were less freauent after the 2nd dose. Vaccine associated rash was mild (mean 14 lesions, ra'nge 1-100). Vaccine type virus was isolated from 1 adult with a total of 8 lesions, 1 mo. after vaccination; there was no spread of vaccine virus to others. Seroconversions to VZV, measured by fluorescent antibody to membrane antigen (FAMA) were: after 1 dose 1361169 (80%), & after 2 doses 1141121 (94%). 22 seroconverted only after the 2nd dose; 7 (6%) failed to seroconvert after 2 doses. Positive antibody responses have been detected after 1 yr in 44/67 (66%), after 2-3 yr.in 19/28 (68%), & after 4-6 yr in 10113 (77%). Ten have had a household exposure to varicella after as long as 7 years (mean 3 yrs); 6 (60%) developed at least some evidence of clinical varicella with 1-40 lesions (mean 16) but no toxicity. Seropositives (5110) rarely developed clinical symptoms; 1 had 1 vesicle. There were a total of 10 cases of mild varicella in adult vaccinees with 1-58 lesions, (mean lo), 4-72 months after immunization. Wild type virus was isolated from 2 MDs, but there was n o spread. Clinical infection was likely to occur in those seronegative at exposure (718, 88%) but the illness was still very mild. Varicella vaccine has the potential to control but not prevent nosocomial varicella. Varicella vaccine is less protective for healthy adults than for healthy children, but it modifies the illness even if VZV antibodies are no longer detectable. I t has been shown t h a t Herpes Simplex Virus (HSV) and Varicel l a -z o s t e r Vi N S (VZV) share a n t i genic determinants and t h a t t h e VZV genome contains homologous regions t o HSV-1 and HSV-2 genomes. More recently Edson, e t a l , found t h a t t h e envelope glycoproteins HSV gB and VZV gp63 share comnon antigens and t h a t cross r e a c t i v e anti-HSV polyclonal and monoclonal antibody can n e u t r a l i z e VZV infection. Because of t h e s e common antigens, we sought t o determine i f administration of LVV i n c h i l d r e n can cause cross-reactive immune responses which could confer p a r t i a l immunity t o t h e heterologous viruses. Blood was obtained froin 43 children a t t h e time of LVV vaccine and t h r e e months l a t e r . A control group of 36 age matched children kere t e s t e d t o determine seroconversion r a t e s in t h e absence of vaccine, Antibody response was determined by enzyme-linked immunosorbent assay, A sero-negative range f o r HSV and f o r CMV was established by studying sera obtained from 200 i n d i v i d u a l s of varying ages including newborns, i n f a n t s , and adults. Seroconversion r a t e f o r t h e immunized population was 0 of 4 3 i n f a n t s f o r HSV and 1 of 40 f o r CMV; respective r a t e s f o r t h e control population were 2 of 35 and 1 of 36. (NS) W e conclude t h a t immunization with LVV vaccine o f f e r s no heterologous antibody protection t o HSV and CMV i n children. (NEJH 1986; 315) . We now report the IgG subclass composition of Hib PS AB i n VP who recovered from i n f e c t i o n , and t h e i r IgG responses t o Pn vaccine. 14/41 ( : A X ) VP were considered to be AB responders t o Hib disease ( > 1 ug/ml of Hib PS Ab i n convalescent s e r a a s measured by a Farr assay) compared with 14/25 (56%) unvaccinated p a t i e n t s with Hib disease of s i m i l a r ages (P=.08). In 10 responder VP (mean age=34 mo), the geo. mean convalescent IgG, G 1 and G2 Hib PS AB a s zeasured by ELISA, were 0.97, 0.69 and 0.09 pg/ml, respectively. The IgG and G1 values were 10-fold lower than those i n convalescent s e r a from 14 unvaccinated responder p a t i e n t s (mean age = 37 mo) (9.24, 7.37 and 0.2 pg/ml, respectively; P<0.01). 18 of 41 tiib VP (mean age of 40 mo) were vaccinated with 23-valent Pn PS. They showed s i g n if i c a n t increases i n geo. mean recip. serum IgG t i t e r s t o P-3 (107 to 1936, P<0.001) and to P-23 (52 t o 120, P<0.02). However, the geo. mean Pn t i t e r s i n post-immune serum of t h e Hib VP group were lower than those of 15 immunized healthy children (mean age=41 mo) (P-3: 3350, P<0.05; P-23: 279, P=0.10). Thus, VP have d e f i c i e n t IgG responses to Hib PS following recovery from Hib disease, and the subclass most affected is GI. Hib VP can respond to Pn PS vaccine but t h e i r IgG responses a r e lower than those of healthy children. D E W REACTIVIlY TO HUMAN CYTOMEGALOVIRUS (CMV). Renu Gupta. Eva Gonczol. John Ianacone. Karen Connor. Stanle A. Plotkin. Division of I n f e c t i o u s Disesses. The C:ldrents Hospital of Philadelphia. and t h e Wistar I n s t i t u t e . Philadelphia, PA.
S t . Louis. Hib PS-vaccinated p a t i e n t s (VP) who develop ~i b d i s e a s e have d e f i c i e n t serum antibody (AB) responses t o Hib PS d e s p i t e normal concentrations of I g and tetanus AB
A s k i n t e s t f o r immunity t o human CMV i s described i n which s k i n induration i s measured a f t e r intradermal i n j e c t i o n of heat-inactivated Tome s t r a i n CMV antigen. Randomly s e l e c t e d healthy young adult males and non-pregnant females were prescreened f o r evidence of p a s t i n f e c t i o n with CMV using a l a t e x agglutination t e s t . Each individual w a s inoculated with 100 ul of t r~t srstieen (50 ug) prepared froni serum-free supernatants of CMV-infected MRC-5 c e l l o (inactivated a t 56OC f o r 6 h r s ) . Candida e x t r a c t (1:1000) and non-infected MRC-5 c e l l l y s a t e s . CMV s e r o p o s i t i v e individuals e l i c i t e d p o s i t i v e s k i n reactions t o both t h e Candida e x t r a c t and t h e t e s t antigen. No response was observed a t t h e MRC-5 c e l l l y s a t e inoculation s i t e . Seronegative individuals who were negative t o t h e t e s t antigen a t t h e s t a r t of t h e study, developed a p o s i t i v e response 8 days a f t e r intramuscular immunization with l i v e attenuated Tome s t r a i n CMV. This response a l s o c o r r e l a t e d with i n v i t r o CMV-induced lymphocyte p r b l i f e r a t i o n of peripheral blood lymphocytes from t h e immunized individuals and p e r s i s t e d f o r a t l e a s t 93 days.
In guinea pig experiments with human W. those a n i n~a l s immunized with p u r i f i e d CMV. a v i r u s envelope preparation, o r a 130-55K glycoprotein complex ( i s o l a t e d by immunoadsorbent column chromatography), developed strong skin reactions t o intradermal i n j e c t i o n of 5 ug of each of these antigens. A weak reaction was a l s o observed t o v i r a l capsid antigen. No reactions were observed i n non-immune animals.
